FibroGen to Report Second Quarter 2020 Financial Results
July 23 2020 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020
financial results on Thursday, August 6 after the market close.
FibroGen will also conduct a conference call on that day at 5:00
p.m. ET (2:00 p.m. PT) with the investment community to further
detail the company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the FibroGen website at
https://fibrogen.gcs-web.com/events-and-presentations/events. It is
recommended that listeners access the website 15 minutes prior to
the start of the call to download and install any necessary audio
software.
Dial-In InformationLive (U.S./Canada): (877)
658-9081Live (International): (602) 563-8732Confirmation number:
8363719
A replay of the webcast will be available shortly after the call
for a period of two weeks. To access the replay, please dial (855)
859-2056 (domestic) or (404) 537-3406 (international), and use
passcode 8363719.
About FibroGenFibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing and
commercializing a pipeline of first-in-class therapeutics. The
company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines to treat unmet needs. The Company is
currently developing and commercializing roxadustat, an oral small
molecule inhibitor of HIF prolyl hydroxylase activity, for anemia
associated with chronic kidney disease (CKD). Roxadustat is also in
clinical development for anemia associated with myelodysplastic
syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab,
an anti-CTGF human monoclonal antibody, is in clinical development
for the treatment of idiopathic pulmonary fibrosis (IPF), locally
advanced unresectable pancreatic cancer, Duchenne muscular
dystrophy (DMD), and coronavirus (COVID-19). For more information,
please visit www.fibrogen.com.
Contact: FibroGen, Inc.
Media Inquiries: Sara Iacovino 1.703.474.4452
sara.iacovino@gcihealth.com
Investors: Michael Tung, M.D.Corporate Strategy / Investor
Relations1.415.978.1434mtung@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024